|3.||Whooping Cough (Pertussis)
|1.||Locht, Camille: 41 articles (09/2015 - 04/2002)|
|2.||Halperin, Scott A: 41 articles (09/2015 - 05/2002)|
|3.||Centers for Disease Control and Prevention (CDC): 34 articles (10/2014 - 02/2002)|
|4.||Aaby, Peter: 29 articles (01/2015 - 11/2002)|
|5.||Guiso, Nicole: 28 articles (10/2015 - 08/2004)|
|6.||Schuerman, Lode: 27 articles (01/2014 - 11/2002)|
|7.||Mooi, Frits R: 24 articles (04/2015 - 06/2002)|
|8.||Harvill, Eric T: 23 articles (12/2015 - 07/2002)|
|9.||He, Qiushui: 23 articles (06/2014 - 07/2004)|
|10.||Cherry, James D: 21 articles (06/2015 - 03/2002)|
09/22/2015 - "Several observational studies provide evidence that acellular pertussis vaccines (aP) are less protective against pertussis disease than highly effective whole-cell pertussis vaccines (wP), however, concerns have been raised that some of these findings may be confounded by age. "
01/01/1997 - "Vaccine efficacy of the most efficacious acellular pertussis vaccines in the three recent placebo-controlled clinical trials, when estimated using the primary clinical case criterion, does not change substantially with the inclusion of serological confirmation in addition to culture confirmation. "
01/01/2015 - "Booster vaccination for teenagers and development of highly efficacious pertussis vaccines are needed."
10/01/2014 - "First generation whole-cell (wP) and second generation acellular (aP) pertussis vaccines have been highly effective in preventing childhood deaths due to pertussis, yet both vaccines have drawbacks that have limited their long-term usefulness. "
04/01/2007 - "Since the efficacy of the currently available acellular pertussis vaccines is, at the best, the same as that of the whole-cell vaccines, any improvement of the current status cannot be expected. "
12/01/2006 - "Administering all 5 doses of pertussis vaccine and the fifth dose at age 5 years with at least 36 months between the fourth and fifth doses provided the best protection against pertussis among children and adolescents in this outbreak."
07/15/2002 - "Thus, even after partial vaccination, acellular pertussis vaccine is highly effective in preventing hospitalizations for pertussis."
03/01/1991 - "These findings suggest that, since its introduction, the whole-cell pertussis vaccine produced in South Africa has been highly effective in controlling whooping cough. "
05/01/1985 - "The incidence of pertussis has been dramatically reduced in many areas of the world over the past 25 years by the use of pertussis vaccine. "
01/01/1997 - "Household studies in the two recently concluded Swedish pertussis vaccine efficacy trials demonstrated that one monocomponent and one five-component candidate acellular pertussis vaccine had reasonably good protective efficacy against clinically typical pertussis after household exposure. "
08/01/2014 - "The acellular pertussis antigens have proven efficacy and real-world effectiveness. "
06/29/2012 - "Immunogenicity against pertussis antigen was significantly greater in the interchangeable vaccinated group compared to the control group, and 57% of the interchangeable vaccinated subjects achieved high levels of protective immunity (45.2 ± 21.5 E U/mL). "
11/01/2009 - "pertussis-derived antigens, confer efficient protection against B. "
03/01/1989 - "pertussis was dependent on the dose of rat testicular homogenate in the inoculum and found to be effective only at lower doses of antigen (10 mg/rat). "
08/28/2013 - "The aim of our study was to determine the antibody concentrations against pertussis antigens in cord and maternal blood in both preterm and term infant-mother pairs and to evaluate the efficacy of transplacental antibody transfer. "
07/01/2014 - "In addition to antibodies, Th1-type T cell responses are also important for long-lasting protection against pertussis. "
04/01/1999 - "These preliminary data suggest that CMI may have an important role in protection against clinical pertussis but do not exclude a role for antibodies. "
12/01/2005 - "pertussis induced rapid neutrophil recruitment and was rapidly cleared from the lungs by adoptively transferred antibodies. "
12/01/2001 - "A statistically significant correlation was found between the level of PTox-induced antibodies and protection against pertussis. "
01/01/2014 - "As in subjects primed with 4 prior doses, we observed that antibodies markedly declined by 5 y of age, calling for the administration of a pre-school booster dose in order to ensure continued protection against pertussis. "
|5.||Diphtheria-Tetanus-Pertussis Vaccine (DPT Vaccine)IBA
01/01/2009 - "A Japanese DPT vaccine dose of 0.2 mL thus proved effective against pertussis in adults."
05/01/1990 - "The point estimate of protective efficacy of the acellular DTP vaccine against typical pertussis was (6/10 - 1/9)/(6/10) x 100 = 81%. "
10/01/1998 - "We analyzed vaccine efficacy of an acellular pertussis component DTP vaccine (DTaP) and a whole cell pertussis component DTP vaccine (DTP) by compliance category. "
01/01/1992 - "[Improvement in the laboratory methods of assessing the safety of the of the pertussis component of DPT vaccine adsorbed]."
11/01/2013 - "[Preclinical studies of an adsorbed diphtheria-tetanus-pertussis vaccine (ADTP-vaccine) with acellular pertussis component]."
02/01/2013 - "Chemically detoxified pertussis toxoids were able to translocate/internalize into cells at the concentration about 1,000 times higher than the native toxin. "
01/01/2010 - "Mass spectrometric analysis of multiple pertussis toxins and toxoids."
01/01/1963 - "[EFFECT OF TOXOIDS ON THE IMMUNOGENIC VALUE OF THE PERTUSSIS COMPONENT]."
01/01/1997 - "Examination of similarities between diphtheria and pertussis and their toxoids provide insight into vaccine-induced protection to Bordetella pertussis."
10/19/1995 - "There were 312 cases of pertussis (72 in the DTP-toxoids group and 240 in the DT-toxoids group) that met the clinical criterion (paroxysmal cough lasting > or = 21 days) and laboratory criteria for pertussis as defined by the World Health Organization. "
02/01/1997 - "A monocomponent pertussis toxoid vaccine induces significant protection against pertussis for at least 2 years after the third injection. "
09/09/2004 - "We found that routine vaccination with pertussis toxoid vaccine was effective against both hospitalisation with pertussis (VE, 93% for three doses) and non-hospitalised pertussis (VE, 78% for three doses). "
10/19/1995 - "A pharmacologically inert, acellular pertussis-toxoid vaccine that is easily standardized is safe and confers substantial protection against pertussis."
06/01/1999 - "Protection against pertussis with a monocomponent pertussis toxoid vaccine."
04/01/1997 - "In conclusion, the pertussis toxoid vaccine provides protection against pertussis both after household and community exposure."
08/01/2004 - "pertussis was based on the amplification of a section of the IS481 insertion sequence and confirmation of positive results was based on a sequence of the pertussis toxin promoter region. "
10/01/1987 - "pertussis strains were utilized to study the biogenesis of pertussis toxin. "
12/01/2015 - "pertussis lipooligosaccharide (LOS) is suppressed by pertussis toxin (PTX). "
11/01/2015 - "Contribution of pertussis toxin to the pathogenesis of pertussis disease."
10/09/2015 - "Pertussis toxin (PTx), an AB5 toxin and major virulence factor of the whooping cough-causing pathogen Bordetella pertussis, has been shown to affect the blood-brain barrier. "
|9.||Diphtheria-Tetanus-acellular Pertussis Vaccines (Tripedia)FDA Link
08/01/2005 - "Any combination of > or =3 DTP/DTaP vaccine doses for children 6 to 59 months of age was highly protective against pertussis. "
07/17/2015 - "Sweden introduced DTaP vaccines in 1996 after a 17-year hiatus with no general pertussis vaccination and pertussis was still endemic at the time of the studies. "
01/01/2015 - "Pertussis cases aged 2 months-1 year were 90% vaccinated following the current DTaP schedule for their age group in Catalonia, and cases of 5-9 years were 87% fully vaccinated with 5 doses of DTaP vaccine. "
06/01/2014 - "To understand the effect of vaccination in the era of acellular pertussis vaccines (DTaP and Tdap), we assessed if vaccination status is associated with disease severity and duration. "
11/01/2013 - "Undervaccination with DTaP vaccine increases the risk of pertussis among children 3 to 36 months of age."
01/01/1999 - "Pertussis immunization coverage has improved dramatically since the introduction of acellular vaccines. "
01/01/1997 - "Although acellular vaccines may be preferred in some countries because of their lower reactogenicity, we are faced with the fact that a well-prepared whole-cell vaccine still provides the best protection against pertussis."
05/16/2003 - "All tested whole-cell and acellular vaccines were significantly more effective than placebo against pertussis. "
02/01/2012 - "National pertussis surveillance and vaccination coverage data, official pertussis vaccination recommendations, and medical and epidemiological sources related to the use, safety and efficacy of whole-cell and acellular vaccines were analysed. "
08/01/2006 - "Finally, we bring attention to the need of (i) field studies for the measurement of pertussis incidence in adolescents and adults; (ii) better understanding of the transmission dynamics currently occurring in RJ, and (iii) re-evaluation of vaccination strategies with the possible introduction of acellular vaccines for the vaccination of older individuals."
05/01/1998 - "pertussis strains are promising vectors for the simultaneous protection against pertussis and heterologous diseases by a single intranasal administration."
07/01/2005 - "Bordetella pertussis, the etiologic agent of whooping cough, is a highly infectious human pathogen capable of inducing mucosal and systemic immune responses upon a single intranasal administration. "
04/12/2006 - "pertussis, induced by a single intranasal administration of BPZE was at least as high as that induced by two injections of commercial acellular vaccine. "
08/01/2002 - "pertussis strain producing Fha44 instead of FHA does not induce anti-FHA antibodies, whereas such antibodies can readily be induced by intranasal administration of purified Fha44. "
12/12/2001 - "pertussis strains were able to prime mice for the production of anti-TTFC serum antibodies upon intranasal administration, suggesting the feasibility of using recombinant attenuated B. "
01/01/2009 - "Vaccine coverage rates were seen to decrease with the follow-up doses of injections required: 89% for the fourth dose of pertusis (whooping cough) vaccine and 91.9% for the fifth does of DTP. "
09/01/2008 - "Most infants (73%) were not vaccinated against pertussis, and the other children had received one or two injections. "
07/01/2006 - "pertussis was comparable to that induced by two injections of acellular vaccine (aPV) in adult mice, but was significantly better than two administrations of aPV in infant mice. "
02/01/2006 - "C57BL/6 mice were immunized three times with the peptide I-Abetab62-76 in Alum+killed pertussis organisms (PT) prior to two injections with tAChR. "
12/11/1999 - "However, when such combinations contain an acellular pertussis component (Pa), the antibody response to Hib is lower than that with separate injections and doubts have been raised about their efficacy. "
|3.||Drug Therapy (Chemotherapy)
08/01/2001 - "While universal immunisation represents the mainstay of prevention, the purpose of this review is to summarise the current options for antimicrobial chemotherapy of pertussis. "
08/01/2001 - "Current pharmacotherapy of pertussis."
02/15/1982 - "[Modern concepts of drug therapy of whooping cough]."
08/01/1961 - "[Chemotherapy of experimental whooping cough infection with 4,4'-diisobutyryldiaminodiphenyl sulfone]."
07/01/1984 - "Twenty-seven children with various childhood malignancies who were in clinical remission and receiving maintenance chemotherapy were given diphtheria-pertussis-tetanus (DPT) immunizations. "
10/01/1999 - "Although epidemiologic investigations of outbreaks have suggested a benefit, there have been no prospective studies evaluating the efficacy of chemoprophylaxis in preventing secondary cases of pertussis. "
01/14/2011 - "The elevated incidence of pertussis and the burden of response placed on health departments warrants exploring the impact of alternative response and chemoprophylaxis strategies."
05/01/2010 - "pertussis cases in any of the exposed children, regardless of whether or not chemoprophylaxis was taken. "
01/12/2008 - "Doctors should always ascertain the presence of a newborn infant in the household of pertussis patients and consider chemoprophylaxis immediately, even ahead of notification. "
03/01/2006 - "Pertussis chemoprophylaxis is indicated for contacts at risk of death or of severe complications if infected with Bordetella pertussis; e.g. "
12/02/2015 - "With no specific therapeutics to treat disease, pertussis continues to cause considerable infant morbidity and mortality. "
05/01/1940 - "Prophylactic Inoculation Against Whooping-Cough: (Section of Therapeutics and Pharmacology)."
08/01/1928 - "Physical Therapeutics: Ultra-Violet Radiation in the Treatment of Pertussis."
04/01/2012 - "Our results demonstrate that the baboon provides an excellent model of clinical pertussis that will allow researchers to investigate pertussis pathogenesis and disease progression, evaluate currently licensed vaccines, and develop improved vaccines and therapeutics."
08/01/1946 - "Interim notes on the therapeutics of bismuth, antimony, zinc, iron, and copper arsanilate in the treatment of malignant disease, syphilis, yaws, leprosy, tuberculosis, whooping cough and some minor complaints in the African."